Skip to content
DraconiticResearch
Search Sources API
186,541 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries

  • Ana Caroline Zimmer Gelatti1,2,3
  • Eldsamira Mascarenhas1,4,5
  • Guilherme Harada1,6
  • Sofia Vidaurre Mendes1,4,5
  • Vladmir Claudio Cordeiro de Lima1,7
7 affiliations
  1. 1Grupo Brasileiro de Oncologia Torácica
  2. 2Grupo Oncoclínicas
  3. 3Hospital São Lucas Pontifícia Universidade Católica do Rio Grande do Sul (PUC/RS)
  4. 4D’Or Oncology
  5. 5D’Or Institute for Research and Education (IDOR)
  6. 6Oncology Center, Hospital Sírio-Libanês
  7. 7Thoracic Cancer Reference Center - A. C. Camargo Cancer Center
Open at sourcePDFDOICite

Abstract

The management of advanced EGFR -mutated non-small cell lung cancer (NSCLC) has evolved from limited targeted options to multiple effective first-line strategies, improving survival but increasing toxicity and treatment burden. This narrative review synthesizes evidence on first-line therapies, integrating clinical outcomes, toxicity profiles, and patient-centered considerations. Recent advances introduce trade-offs between efficacy and tolerability. Patients often prioritize symptom control, functional status, and time outside the healthcare system over modest gains in survival. Treatment selection must account for adverse events, monitoring requirements, and multidisciplinary care. In settings with limited access to molecular testing and novel therapies, such as Brazil and other middle-income countries, disparities further influence decisions. Optimal treatment requires balancing efficacy with safety, feasibility, and patient preferences; therefore, shared decision-making is essential for aligning clinical benefit with real-world constraints and enabling personalized care.

Related

  1. Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC — Primary Analysis of the ATORG-003 Phase 2 Trial
    Aaron C. Tan, Tae Min Kim, Siqin Zhou +11
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
    Haruhiko Yamazaki, Nobuyasu Suganuma, Mei Kadoya +3
    Endocrine JournalPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE
  3. Cost-effectiveness of inavolisib plus palbociclib/fulvestrant versus palbociclib/fulvestrant for PIK3CA-mutated advanced breast cancer in China
    Zuojuan Xiang, Xiaojuan Chen, Ling Ma
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJ
  4. Chinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safety
    Xiaohong Li, Die Qian, Shuai Liu +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  5. Shared Decision-Making and Decision Support in Advanced Chronic Kidney Disease: A Systematic Review of Models, Treatment Pathways, and Patient-Centered Outcomes
    Awais Naeem, Zulfiqar Ashraf, Sajjad Ali +8
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{gelatti2026optimizing,
  title = {{Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries}},
  author = {Ana Caroline Zimmer Gelatti and Eldsamira Mascarenhas and Guilherme Harada and Sofia Vidaurre Mendes and Vladmir Claudio Cordeiro de Lima},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1940079},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1940079/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries
AU  - Ana Caroline Zimmer Gelatti
AU  - Eldsamira Mascarenhas
AU  - Guilherme Harada
AU  - Sofia Vidaurre Mendes
AU  - Vladmir Claudio Cordeiro de Lima
PY  - 2026
DA  - 2026/10/21
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1940079
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1940079/full
AB  - The management of advanced EGFR -mutated non-small cell lung cancer (NSCLC) has evolved from limited targeted options to multiple effective first-line strategies, improving survival but increasing toxicity and treatment burden. This narrative review synthesizes evidence on first-line therapies, integrating clinical outcomes, toxicity profiles, and patient-centered considerations. Recent advances introduce trade-offs between efficacy and tolerability. Patients often prioritize symptom control, functional status, and time outside the healthcare system over modest gains in survival. Treatment selection must account for adverse events, monitoring requirements, and multidisciplinary care. In settings with limited access to molecular testing and novel therapies, such as Brazil and other middle-income countries, disparities further influence decisions. Optimal treatment requires balancing efficacy with safety, feasibility, and patient preferences; therefore, shared decision-making is essential for aligning clinical benefit with real-world constraints and enabling personalized care.
SN  - 2234-943X
ER  -